VEMURAFENIB EFFECTIVE IN NSCLC WITH BRAF-V600 MUTATIONS BUT NOT BRAF NON-V600 MUTATIONS
The authors of this report provide data from a prospective trial to evaluate the benefit of vemurafenib monotherapy for non small cell lung cancer (NSCLC) patients with BRAF-V600 and non-V600 mutations. In the V600 cohort, 43 of 96 patients experienced an objective response, but there were no responses for those with non-V600 mutations. Vemurafenib monotherapy […]
VEMURAFENIB EFFECTIVE IN NSCLC WITH BRAF-V600 MUTATIONS BUT NOT BRAF NON-V600 MUTATIONS Read More »
